Company / PP&E (Net)
Summit Therapeutics Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.1M
FY2025
5-year range
$204.0K / $1.1M
FY2021-FY2025
Trend
+316.9%
vs FY2024
Sector context
#156 of 193
Health Care
What the data says
PP&E (Net) changed +317% YoY in FY2025, a notable deviation from the 6-year average annual change of +55%.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +7.9%.
Improved from $204,000 to $1M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +5.3%
- 5-Year CAGR
- +7.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 193This company $1.1M Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.9%, indicating consistent growth.
- In FY2025, pp&e (net) increased 316.9% year-over-year.
- Ranks #156 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | +316.9% |
| FY2024 | $254.0K | +24.5% |
| FY2023 | $204.0K | -77.5% |
| FY2022 | $906.0K | +30.5% |
| FY2021 | $694.0K | -4.3% |
| FY2020 | $725.0K | +40.0% |
| FY2019 | $518.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026